Published on 9 May 2024 on Simply Wall St. via Yahoo Finance
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest...
Editas Medicine, Inc. (NASDAQ:EDIT) just released its latest quarterly report and things are not looking great. Statutory earnings fell substantially short of expectations, with revenues of US$1.1m missing forecasts by 84%. Losses exploded, with a per-share loss of US$0.76 some 31% below prior forecasts. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Editas Medicine after the latest results.
Check out our latest analysis for Editas Medicine
